France: the Académie de Médecine and the Senate report

What did the French Academy of Medicine warn in 2022, and what did the 2024 Senate report recommend?

France’s debate on medical pathways for gender-distressed minors has often been described as a dispute between “affirmative” care and a more exploratory clinical approach. The national record is more complicated than that shorthand suggests. France has had specialist hospital consultations, but no final, nationwide clinical guideline specifically governing the care of minors. The Haute Autorité de santé (HAS), France’s independent health authority, began a new minors’ guidance project in May 2026. This is important: neither a political report nor a parliamentary vote is a substitute for a clin

Background

France’s debate on medical pathways for gender-distressed minors has often been described as a dispute between “affirmative” care and a more exploratory clinical approach. The national record is more complicated than that shorthand suggests. France has had specialist hospital consultations, but no final, nationwide clinical guideline specifically governing the care of minors. The Haute Autorité de santé (HAS), France’s independent health authority, began a new minors’ guidance project in May 2026. This is important: neither a political report nor a parliamentary vote is a substitute for a clinical guideline developed through a formal health-technology and evidence-review process. ([has-sante.fr](https://www.has-sante.fr/jcms/p_3892586/fr/transidentite-accompagnement-du-mineur-et-de-son-entourage-et-soins-proposes-note-de-cadrage))

Two documents became especially influential. The first was the Académie nationale de médecine’s February 2022 rapid communication, La médecine face à la transidentité de genre chez les enfants et les adolescents. The second was La transidentification des mineurs, published in March 2024 under the leadership of Senator Jacqueline Eustache-Brinio. The latter is routinely called a “Senate report”, but precision matters: it was a report by the Les Républicains group in the Senate, not a report adopted by the Senate as an institution, nor a HAS recommendation. The distinction is confirmed by the Défenseur des droits, France’s independent rights body. ([academie-medecine.fr](https://www.academie-medecine.fr/la-medecine-face-a-la-transidentite-de-genre-chez-les-enfants-et-les-adolescents/))

What the documents say

The Academy’s 2022 warning

The Academy noted a sharp rise in young people presenting for gender-related care, first observed in North America and northern Europe and later in France. It described several possible explanations, including greater social acceptance, examples in a young person’s immediate circle and extensive social-media use. It also referred to an “epidemic-like” pattern. These were the Academy’s stated concerns and hypotheses, rather than settled causal findings. ([academie-medecine.fr](https://www.academie-medecine.fr/la-medecine-face-a-la-transidentite-de-genre-chez-les-enfants-et-les-adolescents/))

Its central clinical warning was explicit: “great medical caution” was required because children and adolescents are psychologically vulnerable and because available treatments can have significant adverse effects or serious complications. It listed possible concerns associated with puberty blockers or cross-sex hormones, including effects on growth, bone strength, fertility and emotional or intellectual development. It further stressed the irreversible character of surgical interventions, specifically referring to mastectomy as available in France from age 14. ([academie-medecine.fr](https://www.academie-medecine.fr/la-medecine-face-a-la-transidentite-de-genre-chez-les-enfants-et-les-adolescents/))

The Academy’s most consequential point was epistemic. It said there was no test capable of distinguishing a persistent, “structural” gender dysphoria from a transient adolescent dysphoria. It therefore recommended psychological support for the young person and parents for as long as possible; cautious decisions on blockers or cross-sex hormones only where a wish to transition persisted, within multidisciplinary case conferences; appropriate clinical training; and more clinical, biological and ethical research. It also urged parental vigilance concerning heavy social-media use. ([academie-medecine.fr](https://www.academie-medecine.fr/la-medecine-face-a-la-transidentite-de-genre-chez-les-enfants-et-les-adolescents/))

Thus, the Academy did not endorse an automatic medical pathway, but it did not recommend legal prohibition either. Its model was extended assessment, family support, multidisciplinary scrutiny and restraint where future identity, capacity and treatment effects could not reliably be predicted. That distinction is frequently lost in summaries of the French debate. ([academie-medecine.fr](https://www.academie-medecine.fr/la-medecine-face-a-la-transidentite-de-genre-chez-les-enfants-et-les-adolescents/))

The 2024 Les Républicains group report

The March 2024 report was much broader and more prescriptive. It recorded 67 experts heard during 35 hours of hearings and ended with 15 recommendations. It used the term transidentification, which is not neutral terminology: the authors said they used it to distinguish established transsexualism from what they regarded as a newer phenomenon of children and adolescents identifying as trans. Readers should therefore treat the report as a parliamentary-political intervention with a declared conceptual framework, not as a consensus medical review. ([observatoirepetitesirene.org](https://www.observatoirepetitesirene.org/_files/ugd/49b30a_e25fe83f43e5431b8c447ad27aa23e3e.pdf))

Its medical recommendations were substantially stricter than the Academy’s. It proposed that initial assessment and diagnosis take place in local child and adolescent mental-health teams; that psychiatric or psychotherapeutic care for the child and family come first where psychopathology or neurodevelopmental conditions were present; and that referral to a specialist gender service occur only where gender-related distress had persisted since early childhood and no major associated psychopathology was present. It proposed banning puberty blockers for gender dysphoria, banning cross-sex hormones for all minors, banning gender reassignment surgery for minors, providing dedicated hospital support for detransitioners and commissioning systematic evidence reviews. ([observatoirepetitesirene.org](https://www.observatoirepetitesirene.org/_files/ugd/49b30a_e25fe83f43e5431b8c447ad27aa23e3e.pdf))

The report also made recommendations outside medicine: repeal of the September 2021 Education Ministry circular on gender identity in schools; use of civil-register sex and name in schools; protection of single-sex toilets, showers and changing rooms; tighter controls on external organisations working in schools; and administrative forms restricted to male and female sex categories. ([observatoirepetitesirene.org](https://www.observatoirepetitesirene.org/_files/ugd/49b30a_e25fe83f43e5431b8c447ad27aa23e3e.pdf))

The positions

The Academy’s position was cautious rather than prohibitionist. It accepted that some young people experience serious distress and need care, but argued that uncertainty about persistence, vulnerability during adolescence and potentially serious treatment effects justified a slower, psychologically supported and multidisciplinary approach. Its statement sits closer to clinical precaution than to a complete legislative settlement. ([academie-medecine.fr](https://www.academie-medecine.fr/la-medecine-face-a-la-transidentite-de-genre-chez-les-enfants-et-les-adolescents/))

The Les Républicains group took the stronger view that the evidential weaknesses and irreversible stakes justified statutory limits. Its recommendations translated directly into a bill introduced on 19 March 2024. The Senate amended that bill before passing it on 28 May: it did not retain an outright blocker ban, instead proposing specialist reference centres, multidisciplinary review, assessment of capacity and contraindications, and a two-year interval after first consultation before an initial prescription. It retained the proposed prohibition of cross-sex hormones and gender reassignment surgery for under-18s. The bill was then transmitted to the National Assembly and has not become law. ([senat.fr](https://www.senat.fr/travaux-parlementaires/textes-legislatifs/la-loi-en-clair/proposition-de-loi-visant-a-encadrer-les-pratiques-medicales-mises-en-oeuvre-dans-la-prise-en-charge-des-mineurs-en-questionnement-de-genre.html))

Opponents, including the Défenseur des droits, argued that the proposed restrictions risked infringing children’s rights and creating discrimination based on gender identity. In its Opinion 24-05, published on 6 May 2024, the institution supported individualised care, proper information, the young person’s voice and informed parental consent. It warned against treating trans identity as inherently pathological, while accepting that psychological or psychiatric support may be needed. ([defenseurdesdroits.fr](https://www.defenseurdesdroits.fr/avis-sur-la-proposition-de-loi-visant-encadrer-les-pratiques-medicales-mises-en-oeuvre-dans-la?utm_source=openai))

Interpretation

Beyond Gender’s reading is that the Academy’s 2022 intervention remains the most institutionally significant warning in the French record because it came from a national medical academy and centred the clinical problem that should precede policy: doctors cannot reliably identify which adolescent presentation will persist and which will not. Where treatment can affect fertility, sexual development, bone health and future bodily integrity, uncertainty is not a minor administrative inconvenience. It is the reason for caution.

The 2024 report went further, and some of its language and school-policy proposals are plainly political rather than medical. Yet its core challenge should not be dismissed merely because it was produced by a political group: France lacked national minor-specific guidance, long-term evidence was contested, and the report pressed institutions to confront the difference between a compassionate response to distress and an assumption that medical transition is the appropriate response. The Academy had already made that distinction in more restrained terms.

The Senate’s amendment of the blocker ban is also revealing. It shows that even legislators sympathetic to greater restrictions recognised that the immediate question was not simply “ban or permit”, but who assesses the child, what evidence is required, how capacity is judged, how long assessment should last and who bears responsibility for uncertain outcomes. ([senat.fr](https://www.senat.fr/travaux-parlementaires/textes-legislatifs/la-loi-en-clair/proposition-de-loi-visant-a-encadrer-les-pratiques-medicales-mises-en-oeuvre-dans-la-prise-en-charge-des-mineurs-en-questionnement-de-genre.html))

Open questions

France’s principal unresolved issue is whether the HAS’s forthcoming minors’ guidance will apply systematic evidence standards consistently to social transition, psychotherapy, puberty blockers, cross-sex hormones, surgery, fertility counselling, neurodevelopmental conditions and detransition. The May 2026 HAS scoping document says that the project will cover support for minors, their families and the types of care offered; its eventual recommendations will matter more than either earlier political argument. ([has-sante.fr](https://www.has-sante.fr/jcms/p_3892586/fr/transidentite-accompagnement-du-mineur-et-de-son-entourage-et-soins-proposes-note-de-cadrage))

There are further practical questions: whether France will create a national audit of prescribing and outcomes; whether it will record discontinuation and detransition adequately; whether families will receive balanced information on uncertainty and alternatives; and whether mental-health provision will be improved for all distressed adolescents rather than being addressed only through the lens of gender identity.

On the European timeline

Episodes on this subject

He Helped Ban Conversion Therapy. Now He Regrets It